Table 1 Comparison of baseline characteristics of patients with WHO-MDS or WHO-AMLreceiving azacitidine front-line

AZA first-line, %

100

100

1

100

100

1

100

100

1

Age (years), median (range)

 Age ≥75 years, %

77 (23–93)

57.7

77 (44–93)

59.5

1

0.867

77 (44–93)

59.5

72 (37–87)

38.5

0.682

0.034

72 (37–87)

38.5

71 (42–87)

41.5

0.933

0.737

Male, %

55.0

65.6

0.334

65.6

65.6

1

65.6

77.4

0.323

MRF^a, %

66.7

78.5

0.327

78.5

100^b

0.110

100^b

100^b

1

Therapy-related, %

4.5

8.9

0.229

8.9

9.4

0.906

9.4

11.3

0.677

PB-blasts (%), median (range)

 ≥0 %, %

4 (0–86)

65.8

2 (0–58)

64.6

0.414

0.916

2 (0–58)

64.6

1 (0–19)

44.8

0.564

0.058

1 (0–19)

44.8

0 (0–4)

37.7

0.317

0.434

ECOG PS, %

 Grades 0–1

 Grade 2

 Grades 3–4

67.6

23.4

9.0

69.6

24.2

6.3

0.865

0.909

0.490

69.6

24.2

6.3

80.2

16.7

3.1

0.386

0.241

0.297

80.2

16.7

3.1

83.0

11.3

5.7

0.827

0.308

0.381

IPSS cytogenetic risk group^c, %

 Good

   Normal karyotype

  Intermediate

 Poor

 Not evaluable

50.5

45.1

14.4

21.6

13.5

46.2

38.5

21.8

20.5

11.5

0.602

0.470

0.219

0.865

0.689

46.2

38.5

21.8

20.5

11.5

48.9

45.7

11.7

30.9

7.3

0.781

0.433

0.081

0.147

0.333

48.9

45.7

11.7

30.9

7.3

45.3

30.2

20.8

24.5

9.4

0.710

0.075

0.110

0.390

0.607

RBC-TD, %

55.9

48.1

0.444

48.1

55.2

0.485

55.2

67.9

0.252

PLT-TD, %

27.9

21.5

0.363

21.5

31.3

0.177

31.3

22.6

0.236

Hb (g/dL), median (range)

9.1 (5.8–14.2)

9.1 (6.3–13.4)

1

9.1 (6.3–13.4)

9.1 (6.7–14.2)

1

9.1 (6.7–14.2)

8.9 (2.5–15)

0.964

PLT (G/L), median (range)

50 (7–1270)

66 (6–1100)

0.137

66 (6–1100)

44 (7–1184)

0.036

44 (7–1184)

51 (8–610)

0.473

WBC (G/L), median (range)

2.5 (0.6–96.0)

2.5 (0.6–41.6)

1

2.5 (0.6–41.6)

2.5 (0.8–96.0)

1

2.5 (0.8–96.0)

2.5 (0.6–13.8)

1

ANC (G/L), median (range)

0.5 (0–37.2)

0.7 (0–28.0)

0.856

0.7 (0–28.0)

0.9 (0–42.0)

0.874

0.9 (0–42.0)

1.1 (0.2–10.9)

0.888